1723.1 - Brexucabtagene autoleucel for adult relapsed or refractory B-precursor acute lymphoblastic leukaemia

Page last updated: 22 February 2024

Application Detail

Description of Medical Service

Brexucabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.

Description of Medical Condition

Acute lymphoblastic leukaemia is a blood cancer that appears suddenly and grows rapidly. It starts when immature white blood cells called blasts become cancerous.

Reason for Application

Highly Specialised Therapy - National Health Reform Agreement

Medical Service Type

Therapeutic technology

Previous Application Number/s


Associated Documentation

Application Form

Application Form (Word 699 KB)
Application Form (PDF 984 KB)

Consultation Survey

Consultation Survey (PDF 655 KB)
Consultation Survey (Word 27 KB)

PASC Consultation
Expedited – Bypassing PASC

MSAC Consultation
MSAC consultation input closed Friday, 6 October 2023.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation


Assessment Report


Public Summary Document

Public Summary Document (PDF 1273 KB)
Public Summary Document (Word 892 KB)

Meetings for this Application


Expedited – Bypassing PASC


5-6 October 2023


23-24 November 2023